Second obesity drug candidate from Roche shows early trial success
![](/46/pdcnewsitem/12/49/21/Heading%20image%20(15).png)
Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics.
The experimental pill CT-996, a once-daily pill for the treatment of obesity, demonstrated a placebo-adjusted average weight loss of 6.1% in 4 weeks for obese patients without diabetes stated the Swiss pharmaceutical company. Roche’s takeover of Carmot Therapeutics occurred in December of last year, with a closing deal of US$2.7 billion and an agreement to challenge Novo Nordisk’s and Eli Lilly’s dominance in the weight-loss drug market.
Though mild/moderate gastrointestinal side effects were observed in some patients, Roche have stated that these effects are not dissimilar to those seen in other weight-loss drugs. CT-996 may provide an alternative to obesity patients averse to regular injections. Roche’s drug product, if successful in its commercialisation, joins a long list of competitors to Novo Nordisk’s Wegovy and Ozempic drug products as companies race to release their own products in a booming obesity drug market.
Chief Medical Officer of Roche Levy Garraway commented, “We are pleased to see the clinically meaningful weight loss in people treated with our oral GLP-1 therapy CT-996, which could eventually help patients address both chronic weight management and glycemic control indications.” Given the results in the first of three clinical trial phases, Roche have stated that CT-996 will advance to the second stage. Roche previously acquired another obesity drug candidate, known as CT-388, from the purchase of Carmo Therapeutics. CT-388 provides a similar self-administered injection as those of Novo Nordisk and Eli Lilly’s products.
Source:
Roche touts early trials success of second obesity drug candidate [Accessed July 17, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/roche-reports-positive-early-results-ct-966-obesity-drug-trial-2024-07-17/
Related News
-
News Tumour microproteins could provide basis for cancer vaccines
A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine. -
News Reworked once-daily weight-loss pill from Pfizer to progress
American pharmaceutical giant Pfizer have continued with a reworked version of their weight-loss pill danuglipron, progressing with a once-daily version of the pill. -
News CPHI Online Trend Report: what is pharmaceutical packaging really costing the industry?
The latest CPHI Online Trend Report dives into what it really costs to develop, manufacture, and deploy pharmaceutical packaging that balances sustainability concerns, patient safety, and drug efficacy. -
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance